RA, Jeito and Omega back a small Swiss biotech to enter an I/O field paved by Adaptimmune
A licensing deal worth up to $520 million has been fueling little-known Swiss biotech CDR-Life since May 2020, but the five-year-old startup is ready to haul in traditional venture capital financing.
After Boehinger Ingelheim fully took control of the duo’s collaboration on a preclinical antibody for geographic atrophy — one of the leading causes of blindness — last summer, CDR-Life went to work finding investors to take its platform forward in solid tumors. Filling that funding role are RA Capital Management and Rafaèle Tordjman’s Jeito Capital, who are co-leading CDR-Life’s $76 million Series A with help from Otello Stampacchia’s Omega Funds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.